US2023026686A1PendingUtilityA1
Ascaroside treatment of eosinophilic esophagitis
Est. expiryAug 25, 2036(~10.1 yrs left)· nominal 20-yr term from priority
A61P 1/04A61K 31/4439A61P 37/06A61K 31/56A61K 45/06A61K 31/7028Y02A50/30A61P 3/10A61K 31/7042A61K 35/62A61K 31/4178G01N 33/6869A61K 47/26A61K 31/573
76
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of preventing or treating eosinophilic esophagitis (EoE) comprising administering a composition comprising ascr #7 is described.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A slurry comprising ascr #7 or a pharmaceutically acceptable salt and/or prodrug thereof; and a pharmaceutically acceptable excipient.
2 . The slurry of claim 1 , wherein the pharmaceutically acceptable excipient is selected from sucralose, syrup, honey, applesauce, and topical adherent, or a mixture thereof.
3 . The slurry of claim 2 , wherein the pharmaceutically acceptable excipient is sucralose.
4 . The slurry of claim 1 , wherein the slurry further comprises an agent with an anti-inflammatory effect.
5 . The slurry of claim 4 , wherein the agent with an anti-inflammatory effect is a corticosteroid.
6 . The slurry of claim 5 , wherein the corticosteroid is selected from aldosterone, betamethasone, budesonide, corticosterone, cortisol, cortisone, dexamethasone, fluticasone, hydrocortisone, methylprednisolone, prednisolone, and prednisone.
7 . The slurry of claim 4 , wherein the agent with an anti-inflammatory effect is a proton pump inhibitor.
8 . The slurry of claim 7 , wherein the proton pump inhibitor is selected from dexlansoprazole, esomeprazole, ilaprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole.
9 . The slurry of claim 1 , wherein the slurry further comprises losartan.
10 . The slurry of claim 4 , wherein the slurry further comprises losartan.
11 . The slurry of claim 1 , comprising ascr #7 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
12 . The slurry of claim 11 , wherein the pharmaceutically acceptable excipient is selected from sucralose, syrup, honey, applesauce, and topical adherent, or a mixture thereof.
13 . The slurry of claim 12 , wherein the pharmaceutically acceptable excipient is sucralose.
14 . The slurry of claim 11 , wherein the slurry further comprises an agent with an anti-inflammatory effect.
15 . The slurry of claim 14 , wherein the agent with an anti-inflammatory effect is a corticosteroid.
16 . The slurry of claim 15 , wherein the corticosteroid is selected from aldosterone, betamethasone, budesonide, corticosterone, cortisol, cortisone, dexamethasone, fluticasone, hydrocortisone, methylprednisolone, prednisolone, and prednisone.
17 . The slurry of claim 14 , wherein the agent with an anti-inflammatory effect is a proton pump inhibitor.
18 . The slurry of claim 17 , wherein the proton pump inhibitor is selected from dexlansoprazole, esomeprazole, ilaprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole.
19 . The slurry of claim 11 , wherein the slurry further comprises losartan.
20 . The slurry of claim 14 , wherein the slurry further comprises losartan.Join the waitlist — get patent alerts
Track US2023026686A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.